Paul Matteis
Stock Analyst at Stifel Nicolaus
Total Price Targets
27
Stocks Covered
17
Sectors
Healthcare
Most Recent
Apr 16, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Paul Matteis
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | $30.00 | $21.83 | +37.4% | 1 | Apr 16, 2026 |
| XENE | Xenon Pharmaceuticals Inc. | $89.00 | $56.81 | +56.7% | 1 | Mar 9, 2026 |
| QURE | uniQure N.V. | $14.00 | $19.21 | -27.1% | 1 | Mar 2, 2026 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $131.00 | $82.41 | +59.0% | 1 | Feb 26, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $68.00 | $54.20 | +25.5% | 3 | Feb 24, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $466.00 | $425.06 | +9.6% | 2 | Feb 13, 2026 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $444.00 | $297.62 | +49.2% | 4 | Feb 12, 2026 |
| ACAD | ACADIA Pharmaceuticals Inc. | $25.00 | $21.95 | +13.9% | 2 | Dec 11, 2025 |
| NBIX | Neurocrine Biosciences, Inc. | $183.00 | $131.64 | +39.0% | 2 | Oct 29, 2025 |
| NGNE | Neurogene Inc. | $46.00 | $27.11 | +69.7% | 2 | Nov 20, 2024 |
| ALKS | Alkermes plc | $36.00 | $33.49 | +7.5% | 2 | Nov 4, 2024 |
| RAPP | Rapport Therapeutics, Inc. Common Stock | $35.00 | $34.13 | +2.6% | 1 | Jul 2, 2024 |
| IONS | Ionis Pharmaceuticals, Inc. | $53.00 | $75.86 | -30.1% | 1 | Jun 27, 2024 |
| BIIB | Biogen Inc. | $275.00 | $186.69 | +47.3% | 1 | May 22, 2024 |
| DYN | Dyne Therapeutics, Inc. | $41.00 | $17.50 | +134.3% | 1 | May 20, 2024 |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $29.00 | $13.38 | +116.7% | 1 | Apr 30, 2024 |
| NMRA | Neumora Therapeutics, Inc. Common Stock | $26.00 | $2.53 | +927.7% | 1 | Oct 10, 2023 |
Recent Activity
- Apr 16, 2026— Set$30.00price target onDFTX(Definium Therapeutics, Inc.)
- Mar 9, 2026— Set$89.00price target onXENE(Xenon Pharmaceuticals Inc.)
- Mar 2, 2026— Set$14.00price target onQURE(uniQure N.V.)
- Feb 26, 2026— Set$131.00price target onRYTM(Rhythm Pharmaceuticals, Inc.)
- Feb 24, 2026— Set$68.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Feb 13, 2026— Set$466.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Feb 12, 2026— Set$444.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Dec 11, 2025— Set$25.00price target onACAD(ACADIA Pharmaceuticals Inc.)
- Oct 29, 2025— Set$183.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Oct 6, 2025— Set$495.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Nov 20, 2024— Set$46.00price target onNGNE(Neurogene Inc.)
- Nov 12, 2024— Set$60.00price target onNGNE(Neurogene Inc.)
- Nov 4, 2024— Set$36.00price target onALKS(Alkermes plc)
- Oct 24, 2024— Set$25.00price target onALKS(Alkermes plc)
- Aug 21, 2024— Set$115.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Aug 6, 2024— Set$112.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Jul 2, 2024— Set$35.00price target onRAPP(Rapport Therapeutics, Inc. Common Stock)
- Jun 27, 2024— Set$53.00price target onIONS(Ionis Pharmaceuticals, Inc.)
- Jun 27, 2024— Set$295.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Jun 24, 2024— Set$247.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
Frequently Asked Questions
Who is Paul Matteis?
Paul Matteis is a stock analyst at Stifel Nicolaus covering 17 stocks primarily in Healthcare. They have issued 27 price targets since Feb 11, 2022.
What stocks does Paul Matteis cover?
Paul Matteis currently covers 17 stocks, including ALNY, BMRN, VRTX, ACAD, NBIX.
What is Paul Matteis's latest price target?
Paul Matteis's most recent price target was $30.00 on DFTX (Definium Therapeutics, Inc.), set on Apr 16, 2026.
What is Paul Matteis's highest price target?
Paul Matteis's highest issued price target is $495.00 on ALNY, set on Oct 6, 2025.
More Analysts at Stifel Nicolaus
Coverage based on publicly published price targets. Not investment advice.